SCHEMBL4552093

SCHEMBL4552093

Cc1ccccc1C(=O)C(N)CC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.45
FEN1 P39748 1/20 0.45
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HPGD P15428 3/20 0.42
MYC P01106 1/20 0.42
FFAR1 O14842 2/20 0.42
KMT2A Q03164 1/20 0.41
SLC1A3 P43003 1/20 0.40
SLC1A2 P43004 1/20 0.40
SLC1A1 P43005 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
GAA P10253 1/20 0.40
GABBR2 O75899 1/20 0.40
GABBR1 Q9UBS5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9830781 0.82 ERCC5 (0.41) ERCC5FEN1SLC6A2SLC6A4SLC6A3
SCHEMBL15361966 0.81 MAPT (0.47) HPGDKMT2ASMN1; SMN2TSHRMAPK1
SCHEMBL30367223 0.81 KDM4E (0.48) HPGDKMT2ASMN1; SMN2TSHRGAA
SCHEMBL11235530 0.78 CYP2D6 (0.43) SLC6A2SLC6A4SLC6A3
SCHEMBL9539471 0.77 PTGDR2 (0.41) HPGDKMT2ASLC1A3SLC1A2SLC1A1
SCHEMBL16714061 0.77 HPGD (0.46) ERCC5FEN1SLC6A2SLC6A4SLC6A3
SCHEMBL7799519 0.76 KDM4E (0.58) ERCC5FEN1SLC1A3SLC1A2SLC1A1
SCHEMBL7799518 0.76 KDM4E (0.58) ERCC5FEN1SLC1A3SLC1A2SLC1A1
SCHEMBL7791486 0.76 KDM4E (0.58) ERCC5FEN1SLC1A3SLC1A2SLC1A1
SCHEMBL11133283 0.76 ALKBH5 (0.47) HPGDKMT2ASMN1; SMN2TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638630-B2 Very Late Antigen-4 dependent inflammatory disease; asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders, autoimmune disorders, or atherosclerosis, inflammatory skin disorder; methyl 3-[2-(2,6-dichlorophenyl)-6-quinolinyl]-2-hydroxy-2-propenoate UCB PHARMA S.A. (BE) 2009-12-29 US disclosed
US-20080064720-A1 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors UCB, S.A. (BE) 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064720-A1 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors VCAM1, HRH4, LTA4H ERCC5 3905/4885FEN1 4647/4885SLC6A2 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.